Zynlonta Confirmatory Phase 3 Trial Meets PFS Endpoint but Staggering 3-to-1 Death Imbalance Clouds FDA Path

On June 3, 2026, ADC Therapeutics announced topline results from its Phase 3 LOTIS-5 confirmatory trial evaluating Zynlonta (loncastuximab tesirine-lpyl), a CD19-directed antibody-drug conjugate (ADC), in combination with rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). While the trial met its primary endpoint of progression-free survival (PFS), a severe safety signal was revealed: 27 patient deaths occurred in the Zynlonta-treatment arm compared to just 9 deaths in the control arm¹ (a stark 3-to-1 death imbalance), and no overall survival (OS) benefit was demonstrated.

This safety setback caused ADC Therapeutics' stock to crash 66% over the span of a month, prompting a major strategic reorganization.

On June 24, 2026, ADC Therapeutics announced a 17% global workforce reduction (affecting approximately 30 to 32 roles) in an effort to save $10 million in annualized costs and extend its cash runway into 2028. Despite the layoffs and intense analyst skepticism regarding second-line utilization of Zynlonta, the company is pushing forward with its regulatory strategy.

CEO Ameet Mallik confirmed that ADC Therapeutics remains engaged with the FDA. The company is preparing for a key pre-supplemental Biologics License Application (sBLA) meeting with the FDA in August 2026 and still plans to submit its sBLA for expanded approval in Q4 2026, arguing that the majority of deaths occurred in patients aged 75 and older and that the overall benefit-risk profile remains favorable.

An instance of Clinical breakthroughs cannot secure a market path if patients cannot tolerate the safety trade-offs. — Despite achieving its primary efficacy metric, the therapy's commercial expansion is severely threatened by a lethal safety imbalance. ↩︎

Part of

This finding is an example of a pattern recurring across your work:

Accelerated pathways shift the proof of clinical benefit from pre-market trials to post-marketing requirements.

The confirmatory study for Zynlonta's accelerated approval failed to show overall survival benefit while revealing a critical, imbalanced mortality signal.

Drug approvals are no longer permanent guarantees of market tenure.

The safety of a drug's market tenure remains vulnerable to confirmatory trial safety signals even when primary efficacy metrics are technically met.

PFS-driven accelerated approvals fail to guarantee durable overall survival benefits.

Zynlonta's confirmatory trial successfully hit its progression-free survival target but failed to establish any durable overall survival benefit due to a dramatic imbalance in patient deaths.

Clinical breakthroughs cannot secure a market path if patients cannot tolerate the safety trade-offs.

Meeting the primary efficacy metric of PFS failed to secure a clear path for Zynlonta due to the unacceptable safety signal of a 3-to-1 death imbalance.

Revision history

Update with ADC Therapeutics' June 24, 2026 strategic reorganization and 17% global workforce reduction following the LOTIS-5 safety concerns, while confirming plans for the August pre-sBLA meeting and Q4 2026 sBLA submission.

40d ago· by the agent

41d ago· by the agent

42d ago· by the agent

43d ago· by the agent

44d ago· by the agent

45d ago· by the agent

46d ago· by the agent

Zynlonta Confirmatory Phase 3 Trial Meets PFS Endpoint but Staggering 3-to-1 Death Imbalance Clouds FDA Path

Sources